Log in
NASDAQ:SWTX

SpringWorks Therapeutics News Headlines

$66.93
+0.33 (+0.50 %)
(As of 12/2/2020 12:00 AM ET)
Add
Compare
Today's Range
$62.41
Now: $66.93
$67.78
50-Day Range
$54.25
MA: $62.16
$69.10
52-Week Range
$19.50
Now: $66.93
$71.15
Volume196,440 shs
Average Volume217,203 shs
Market Capitalization$3.26 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

SpringWorks Therapeutics (NASDAQ SWTX) News Headlines Today

Source:
SourceHeadline
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Rating of "Buy" by AnalystsSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - December 1 at 1:44 AM
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 6%SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 6%
americanbankingnews.com - November 20 at 6:51 PM
Zacks: Brokerages Expect SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Will Announce Earnings of -$0.32 Per ShareZacks: Brokerages Expect SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Will Announce Earnings of -$0.32 Per Share
americanbankingnews.com - November 16 at 1:20 AM
SpringWorks Therapeutics (NASDAQ:SWTX) Posts Quarterly  Earnings Results, Misses Expectations By $0.06 EPSSpringWorks Therapeutics (NASDAQ:SWTX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS
americanbankingnews.com - November 13 at 2:20 PM
SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 52-Week High at $67.46SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 52-Week High at $67.46
americanbankingnews.com - November 13 at 12:46 PM
SpringWorks Therapeutics EPS misses by $0.02SpringWorks Therapeutics EPS misses by $0.02
seekingalpha.com - November 12 at 9:46 AM
SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business HighlightsSpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - November 12 at 9:46 AM
SpringWorks Therapeutics (NASDAQ:SWTX) Trading 11.4% Higher SpringWorks Therapeutics (NASDAQ:SWTX) Trading 11.4% Higher
americanbankingnews.com - November 10 at 11:18 PM
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline ProgressesAllogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
nasdaq.com - November 4 at 1:24 PM
SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% HigherSpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher
nasdaq.com - October 12 at 4:23 PM
SpringWorks Therapeutics prices equity offering at $51SpringWorks Therapeutics prices equity offering at $51
seekingalpha.com - October 8 at 3:44 AM
SpringWorks initiates $150M equity offeringSpringWorks initiates $150M equity offering
seekingalpha.com - October 7 at 12:17 PM
SpringWorks Inks Deal With Pfizer for Nirogacestat ComboSpringWorks Inks Deal With Pfizer for Nirogacestat Combo
nasdaq.com - October 6 at 4:14 PM
Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalitiesFifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities
nasdaq.com - October 6 at 6:13 AM
Pfizer teams up with SpringWorks to evaluate PF‐06863135 + nirogacestat in multiple myelomaPfizer teams up with SpringWorks to evaluate PF‐06863135 + nirogacestat in multiple myeloma
seekingalpha.com - October 5 at 7:35 AM
Durham firm teams up with competitor to advance cancer treatmentDurham firm teams up with competitor to advance cancer treatment
bizjournals.com - September 21 at 4:07 PM
Precision Bio teams with SpringWorks for PBCAR269A+Nirogacestat combo study in multiple myelomaPrecision Bio teams with SpringWorks for PBCAR269A+Nirogacestat combo study in multiple myeloma
seekingalpha.com - September 21 at 11:07 AM
SpringWorks inks deal for nirogacestat in rare soft-tissue tumorsSpringWorks inks deal for nirogacestat in rare soft-tissue tumors
seekingalpha.com - September 18 at 10:45 AM
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple MyelomaSpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
finance.yahoo.com - September 18 at 10:45 AM
SpringWorks teams up with COG for nirogacestat in pediatric patients with soft tissue tumorsSpringWorks teams up with COG for nirogacestat in pediatric patients with soft tissue tumors
seekingalpha.com - September 16 at 10:17 AM
SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor PatientsSpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients
finance.yahoo.com - September 16 at 10:17 AM
SpringWorks teams up with Janssen in multiple myeloma studySpringWorks teams up with Janssen in multiple myeloma study
seekingalpha.com - September 14 at 7:42 AM
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple MyelomaSpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - September 14 at 7:42 AM
SpringWorks Therapeutics (SWTX) Investor Presentation - SlideshowSpringWorks Therapeutics (SWTX) Investor Presentation - Slideshow
seekingalpha.com - August 13 at 6:58 PM
SpringWorks Therapeutics EPS misses by $0.06SpringWorks Therapeutics EPS misses by $0.06
seekingalpha.com - August 12 at 6:35 PM
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business HighlightsSpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - August 12 at 6:35 PM
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with DesmoidSpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid
bloomberg.com - August 9 at 7:54 AM
SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare ConferenceSpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 4 at 7:06 AM
SpringWorks completes enrollment in late-stage nirogacestat study in connective tissue tumorsSpringWorks completes enrollment in late-stage nirogacestat study in connective tissue tumors
seekingalpha.com - July 22 at 8:38 AM
SpringWorks completes enrollment in late-stage DeFi trial in Desmoid tumorsSpringWorks completes enrollment in late-stage DeFi trial in Desmoid tumors
seekingalpha.com - July 22 at 8:38 AM
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid TumorsSpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
finance.yahoo.com - July 22 at 8:38 AM
Hedge Funds Keep Buying SpringWorks Therapeutics, Inc. (SWTX)Hedge Funds Keep Buying SpringWorks Therapeutics, Inc. (SWTX)
finance.yahoo.com - June 28 at 6:37 PM
Dosing underway in SpringWorks early-stage combination study in multiple myelomaDosing underway in SpringWorks' early-stage combination study in multiple myeloma
seekingalpha.com - June 22 at 9:40 AM
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple MyelomaSpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - June 22 at 9:40 AM
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical TrialBeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
finance.yahoo.com - June 22 at 9:40 AM
IPO Launch: Repare Therapeutics Proposes U.S. IPO TermsIPO Launch: Repare Therapeutics Proposes U.S. IPO Terms
www.thestreet.com - June 17 at 12:09 PM
SpringWorks Therapeutics (SWTX) Presents At Goldman Sachs Global Healthcare Conference - SlideshowSpringWorks Therapeutics (SWTX) Presents At Goldman Sachs Global Healthcare Conference - Slideshow
seekingalpha.com - June 11 at 6:20 PM
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth PlansSpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - June 10 at 8:55 AM
SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceSpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
finance.yahoo.com - June 2 at 8:50 AM
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of DirectorsSpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors
finance.yahoo.com - May 26 at 8:06 AM
SpringWorks Therapeutics EPS beats by $0.04SpringWorks Therapeutics EPS beats by $0.04
seekingalpha.com - May 12 at 5:59 PM
SpringWorks Therapeutics IncSpringWorks Therapeutics Inc
www.bloomberg.com - May 1 at 5:55 PM
Hedge Funds Have Never Been More Bullish On SpringWorks Therapeutics, Inc. (SWTX)Hedge Funds Have Never Been More Bullish On SpringWorks Therapeutics, Inc. (SWTX)
finance.yahoo.com - April 15 at 3:29 PM
SpringWorks Therapeutics: View Ahead Of 2020 CatalystsSpringWorks Therapeutics: View Ahead Of 2020 Catalysts
seekingalpha.com - April 3 at 1:46 PM
SpringWorks Therapeutics Announces Issuance of...SpringWorks Therapeutics Announces Issuance of...
www.benzinga.com - March 18 at 8:58 AM
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039
finance.yahoo.com - March 18 at 8:58 AM
SpringWorks Therapeutics: 4Q Earnings SnapshotSpringWorks Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - March 13 at 12:14 AM
SpringWorks Therapeutics EPS misses by $0.03SpringWorks Therapeutics EPS misses by $0.03
seekingalpha.com - March 12 at 7:13 PM
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - March 12 at 7:13 PM
Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase InhibitorResearchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor
www.bloomberg.com - February 11 at 10:14 PM
This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.